Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Metformin increases pressure pain threshold in lean women with polycystic ovary syndrome.

Kiałka M, Milewicz T, Sztefko K, Rogatko I, Majewska R.

Drug Des Devel Ther. 2016 Aug 3;10:2483-90. doi: 10.2147/DDDT.S109086. eCollection 2016.

2.

Targets to treat metabolic syndrome in polycystic ovary syndrome.

Mahalingaiah S, Diamanti-Kandarakis E.

Expert Opin Ther Targets. 2015;19(11):1561-74. doi: 10.1517/14728222.2015.1101067. Epub 2015 Oct 21. Review.

3.

Effect of Ramadan Fasting on Stress Neurohormones in Women with Polycystic Ovary Syndrome.

Zangeneh F, Salman Yazdi R, Naghizadeh MM, Abedinia N.

J Family Reprod Health. 2015 Jun;9(2):51-7.

4.

The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus.

Rojas J, Chávez-Castillo M, Bermúdez V.

Int J Reprod Med. 2014;2014:797681. doi: 10.1155/2014/797681. Epub 2014 Dec 8. Review.

5.

Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth.

Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, Calvo M, Bermúdez V.

Int J Reprod Med. 2014;2014:719050. doi: 10.1155/2014/719050. Epub 2014 Jan 28. Review.

6.

Polycystic ovary syndrome: effect and mechanisms of acupuncture for ovulation induction.

Johansson J, Stener-Victorin E.

Evid Based Complement Alternat Med. 2013;2013:762615. doi: 10.1155/2013/762615. Epub 2013 Sep 2. Review.

7.

Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial.

Johansson J, Redman L, Veldhuis PP, Sazonova A, Labrie F, Holm G, Johannsson G, Stener-Victorin E.

Am J Physiol Endocrinol Metab. 2013 May 1;304(9):E934-43. doi: 10.1152/ajpendo.00039.2013. Epub 2013 Mar 12.

8.

The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Bargiota A, Diamanti-Kandarakis E.

Ther Adv Endocrinol Metab. 2012 Feb;3(1):27-47. doi: 10.1177/2042018812437355.

9.

The physiological basis of complementary and alternative medicines for polycystic ovary syndrome.

Raja-Khan N, Stener-Victorin E, Wu X, Legro RS.

Am J Physiol Endocrinol Metab. 2011 Jul;301(1):E1-E10. doi: 10.1152/ajpendo.00667.2010. Epub 2011 Apr 12. Review. Erratum in: Am J Physiol Endocrinol Metab. 2012 Dec 15;303(12):E1506.

10.

Insulin resistance influences central opioid activity in polycystic ovary syndrome.

Berent-Spillson A, Love T, Pop-Busui R, Sowers M, Persad CC, Pennington KP, Eyvazaddeh AD, Padmanabhan V, Zubieta JK, Smith YR.

Fertil Steril. 2011 Jun 30;95(8):2494-8. doi: 10.1016/j.fertnstert.2011.03.031. Epub 2011 Apr 12.

11.

Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period.

Sowers MR, McConnell D, Yosef M, Jannausch ML, Harlow SD, Randolph JF Jr.

Ann N Y Acad Sci. 2010 Aug;1204:95-103. doi: 10.1111/j.1749-6632.2010.05523.x.

12.

Family-based analysis of candidate genes for polycystic ovary syndrome.

Ewens KG, Stewart DR, Ankener W, Urbanek M, McAllister JM, Chen C, Baig KM, Parker SC, Margulies EH, Legro RS, Dunaif A, Strauss JF 3rd, Spielman RS.

J Clin Endocrinol Metab. 2010 May;95(5):2306-15. doi: 10.1210/jc.2009-2703. Epub 2010 Mar 3.

Supplemental Content

Support Center